Limulus amebocyte lysate

Source: Wikipedia, the free encyclopedia.

Atlantic horseshoe crab Limulus polyphemus

Limulus amebocyte lysate (LAL) is an aqueous extract of

endotoxins
.

In Asia, a similar Tachypleus amebocyte lysate (TAL) test based on the local horseshoe crabs Tachypleus gigas or Tachypleus tridentatus is occasionally used instead.[1] The recombinant factor C (rFC) assay is a replacement of LAL and TAL based on a similar reaction.[2]

Background

The American medical researcher

gelling, the resulting gel is thought to contain bacterial infections in the animal's semi-closed circulatory system.[3] Modern analysis of the lysate has led to understanding of this system of cascade, with multiple enzymes working in sequence to produce the gel. The entry point of endotoxin-induced clotting is Limulus clotting factor C.[4]

In 1977 the

U.S. Food and Drug Administration (FDA) approved LAL for testing drugs, products and devices that come in contact with the blood. Prior to that date, a much slower and more expensive test on rabbits had been used for this purpose.[5]

Horseshoe crabs are collected and blood is removed from the horseshoe crab's pericardium; some crabs are then returned to the water, while others are sold to be eaten or used as bait. Companies extracting LAL from horseshoe crabs stated before 2008 that mortality rates were below 3%.[6] A 2009 Massachusetts Division of Marine Fisheries study stated that earlier studies found 5 to 15% mortality for males and one estimate of 29% for females. The study itself found 22% for females returned immediately to the water, and 30% for females kept overnight to represent commercial practice.[7] The blood cells are separated from the serum using centrifugation and are then placed in distilled water, which causes them to swell and burst ("lyse"). This releases the chemicals from the inside of the cell (the "lysate"), which is then purified and freeze-dried. To test a sample for endotoxins, it is mixed with lysate and water; endotoxins are present if coagulation occurs.[8]

The LAL test

There are three basic methodologies:

chromogenic. The primary application for LAL is the testing of parenteral pharmaceuticals and medical devices that contact blood or cerebrospinal fluid. In the United States, the FDA has published a guideline for validation of the LAL test as an endotoxin test for such products.[9]

The LAL cascade is also triggered by (1,3)-β-D-glucan, via a different Factor G. Both bacterial endotoxins and (1,3)-β-D-glucan are considered pathogen-associated molecular patterns, or PAMPs, substances which elicit inflammatory responses in mammals.[10]

Overcoming inhibition and enhancement

One of the most time-consuming aspects of endotoxin testing using LAL is pretreating samples to overcome assay inhibition that may interfere with the LAL test such that the recovery of endotoxin is affected. If the product being tested causes the endotoxin recovery to be less than expected, the product is inhibitory to the LAL test. Products which cause higher than expected values are enhancing. Overcoming the inhibition and enhancement properties of a product is required by the FDA as part of the validation of the LAL test for use in the final release testing of injectables and medical devices. Proper endotoxin recovery must be proven before LAL can be used to release product.[11]

Alternatives

Recombinant factor C assay

See also: Atlantic horseshoe crab § Conservation and management

The LAL test is a major source of

recombinant protein substitute for use in the LAL test has been commercially available. Named the recombinant factor C (rFC) assay, it is based on the same Limulus clotting factor C protein, but produced by genetically modified insect cells (the specific factor C sequence used does not necessarily come from the Atlantic horseshoe crab).[5]

Instead of emulating the whole clotting pathway, rFC tests let factor C cleave a synthetic

false-positives. As of 2018, available evidence shows that the rFC test is no worse than the LAL test.[13]

The adoption of the rFC test was slow, which began to change in 2012 when the US

FDA and the European health ministry acknowledged it as an accepted alternative. Its lack of mention in Pharmacopeias remained an issue, as there was no good standard for running the test in production.[13] In 2016, it was added to the European Pharmacopoeia.[5] A patent on rFC also limited adoption until its expiration in 2018.[13]

On 1 June 2020, the United States Pharmacopeia (USP) decided to cancel the proposal to include recombinant technology for endotoxin testing in chapter 85, Bacterial Endotoxins, and start the development of a separate chapter that expands on the use, validation, and comparability of endotoxin tests based on recombinantly derived reagents. A separate guidance-only chapter 1085.1 was proposed by the USP, though comments and feedback published on 11 December 2020 show that pharmaceutical companies and the FDA do not support this chapter, and request for compendial status.[14]

Monocyte activation test

The

pyrogens, basically mirroring the process by which these toxins cause fever in humans (and rabbits, as in the original pyrogen test).[15] A protocol for the MAT test, using cultured cells, is described in the European Pharmacopoeia.[16]

A recent study employing genetically engineered monocytes was able to significantly enhance the sensitivity of monocyte-based detection assays by bringing down the assay-completion time from more than 20 hours to 2–3 hours.[17]

See also

References

  1. ^ Sheng J, Zhou J, Peng Y, Zhu Z, Chen L (1 January 2006). "Tachypleus Amebocyte Lysate Test Using in Transfusion Reaction". Chinese Journal of Nosocomiology (in Chinese).
  2. ^ "Endotoxin Testing Manufacturers and Conservation". www.horseshoecrab.org. Retrieved 10 March 2020.
  3. ^ Greer S. "Frederik Bang". JH Bloomberg School of Public Health. Johns Hopkins Bloomberg School of Public Health.
  4. PMID 24019589
    .
  5. ^ a b c Zhang S (9 May 2018). "The Last Days of the Blue-Blood Harvest". The Atlantic. Retrieved 15 May 2018.
  6. ^ "Crash: A Tale of Two Species - The Benefits of Blue Blood". PBS. 10 June 2008.
  7. ^
    S2CID 35152647. Archived from the original
    (PDF) on 14 June 2010.
  8. ^ "The History of Limulus and Endotoxin". Marine Biological Laboratory. Archived from the original on 28 October 2008.
  9. ^ "Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers". U.S. Food and Drug Administration. Retrieved 5 March 2019.
  10. ^ Sandle T (August 2013). "Pharmaceutical product impurities: considering beta glucans". American Pharmaceutical Review. 16 (5 Supplement S1): 16–19.
  11. ISBN 978-1420020595
    . Retrieved 7 March 2015. Proper endotoxin recovery must be proven before LAL can be used to release product.
  12. PMID 35591980
    .
  13. ^
    PMID 30312293
    .
  14. ^ https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-notices/1085-1-pf-comments-20201211.pdf [bare URL PDF]
  15. ^ "Alternative Endotoxin Testing Methods". www.horseshoecrab.org.
  16. ^ "Monocyte Activation Test: From Validation to GMP Lab testing". American Pharmaceutical Review.
  17. PMID 34952917
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Limulus_amebocyte_lysate&oldid=1197571422"